Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.

PA, Jänne; den Heuvel MM, van; F, Barlesi; M, Cobo; J, Mazieres; L, Crinò; S, Orlov; F, Blackhall; J, Wolf; P, Garrido; A, Poltoratskiy; G, Mariani; D, Ghiorghiu; E, Kilgour; P, Smith; A, Kohlmann; DJ, Carlile; D, Lawrence; K, Bowen; J, Vansteenkiste

doi:10.1001/jama.2017.3438

Public

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.

Shared by NobleBlocks on May 1, 2017 • 12:00 AM UTC

Authors:

Jänne PA

van den Heuvel MM

Barlesi F

Abstract

Importance There are no specifically approved targeted therapies for the most common genomically defined subset of non-small cell lung cancer (NSCLC), KRAS-mutant lung cancer.Objective To compare efficacy of the mitogen-activated protein kinase kinase (MEK) inhibitor selumetinib + docetaxel with doc...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!